Table 2: Maximal relative response for phenylephrine in relation to the presence of 2-MeS-ADP, ticagrelor and the dose of aspirin in arteries without vascular endothelium.

[%]2

Control rats: PHE (10 μM/L)20
Ticagrelor pretreated rats: PHE (10 μM/L) + ticagrelor (1 μM/L) + 2-MeS-ADP (10 μM/L)20
Low-dose aspirin pretreated rats: PHE (10 μM/L)21 nsa
Ticagrelor and low-dose aspirin pretreated rats: PHE (10 μM/L) + ticagrelor (1 μM/L) + 2-MeS-ADP (10 μM/L)21   
  
nsc
High-dose aspirin pretreated rats: PHE (10 μM/L)21 nsa
Ticagrelor and high-dose aspirin pretreated rats: PHE (10 μM/L) + ticagrelor (1 μM/L) + 2-MeS-ADP (10 μM/L)21 nsa  
  
nsd

PHE: phenylephrine; 2-MeS-ADP: stable analogue of adenosine diphosphate; 1number of concentration-response curves used for calculations; 2 : calculated as a percent of maximal response for PHE; a value calculated versus controls; b value calculated versus PHE + low-dose aspirin; c value calculated versus PHE + ticagrelor + 2-MeS-ADP; d -value calculated versus PHE + high-dose aspirin.